RBC Capital analysts provided a preview of Evolent Health, Inc. (NYSE:EVH) ahead of the upcoming Q1 earnings results, scheduled on May 3.
According to the analysts, the company remains one of their favorite value-based care ideas based on a strengthening macro backdrop and accelerating cross-selling/conversion momentum, which primes the model for steady long-range EBITDA growth.
RBC Capital expects investor focus to be on assessing management’s progress toward both its $180-200 million 2023 EBITDA guidance and its targeted $300 million 2024 exit rate.
According to the analysts, the two most important drivers are (1) margin progression within its existing risk-bearing contracts –the most impactful near-term EBITDA driver, and (2) continued cross-selling and Performance Suite conversions–the most impactful long-term driver.
At CWEB, we are always looking to expand our network of strategic investors and partners. If you're interested in exploring investment opportunities or discussing potential partnerships and serious inquiries. Contact: jacque@cweb.com